$2245 | Single User
$7945 | Multi User
$15395 | Global License

Biosimilars: US Payer Perspectives [Report Updated: 01-04-2017]

Published by FirstWord Pharma: 01 Apr 2017 | 65371 | In Stock

Introduction

Will biosimilar provide a ‘magic bullet’ to drug prices in the US? Payers speak out…

Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers. While the number of biosimilar approvals in the US still lags behind Europe, a solid foundation continues to be laid by multiple key stakeholder groups. Successes have been seen in key areas, including the approval of the first monoclonal antibody (mAb) biosimilar, Inflectra, and regulatory refinement. But what of the critical opportunities and challenges in the US? How do payers perceive what’s important, and what can companies do to ensure commercial success?

Report Overview

Ten expert US payers from government and commercial backgrounds, and all with experience with biosimilars, share their views on the evolution of the US biosimilars market and what challenges still remain. Biosimilars: US Payer Perspectives details their insights on the current status of the US biosimilars market and how they see things evolving.

Report Features

In-depth interviews reveal over 200 unique and candid insights from ten 10 expert US payers from government and commercial backgrounds

Overview of the key areas of progress in the US biosimilars market during the last year, including an analysis of critical market shaping issues such as clinical data, regulatory progress, commercialisation, legal and policy.

The key issues regarding how the US biosimilars market has evolved and where payers believe future efforts need to be focused, including pricing, market access and contracting.

Detailed case studies on the commercialisation of two biosimilars (Zarxio and Inflectra) and one follow-on biologic (Basaglar), and what payers believe has gone well and where improvements for subsequent launches need to be made.

Updated insights on what the critical challenges and opportunities within the US biosimilars market are today, and what companies can do to navigate these successfully.

Key Benefits

Understand how the US biosimilars market has evolved over the past year and what the stand- out developments were.

Gain insight into the trends that are set to drive high rates of biosimilar adoption in the US, and what issues could slow this adoption down

Gain insight into the role of focused and unbiased education has on biosimilars, and which key stakeholder group payers believe needs to be the key focus of these educational efforts.

Assess the current views on drug pricing in the US, and what impact biosimilars could have on lowering prices and improving patient access.

Critique payer views on the evolving arguments for switching from originator brands to biosimilars, and how FDA regulations and state-level legislation needs to work in concert for this to become a reality.

Navigate the critical opportunities and challenges within the US biosimilars market, and understand what payers see as must-win battles to ensure a successful US biosimilars market.

Key Questions Answered By This Report

How have the key drivers and resistors of biosimilar usage in the US evolved over the past year?

Do payers agree with the current regulatory pathway for biosimilars in the US, and how do they perceive it changing moving forward, particularly in relation to interchangeability?

How do payers expect pricing dynamics within the US biosimilars market to evolve, and what are their expectations in relation to the pricing of originator biologics in response to biosimilar competition?

How have payer views in relation to the key market-shaping issues of switching, automatic substitution, extrapolation of indications, and biosimilar naming changed over the past year, and how have key events in these areas shaped and changed thinking?

What does the future hold for biosimilars in the US; is it a case that biosimilars need to succeed in order to support a more sustainable healthcare system, or will the biosimilars market crumble under the weight of its own expectations?

Expert Views

Each of our experts has a detailed understanding of the US pricing, reimbursement and market access landscape as it relates to biosimilars. To enable them to express candid views, our experts have chosen to remain anonymous.

Clinical Advisor, Pharmacy Benefit Manager

Medical Director, Managed Care Organisation

Chief Medical Officer, National Health Plan

Clinical Pharmacist, Health Insurance Provider

Regional Clinical Manager

VP, National Health Insurance Provider

Chief Medical Officer, National Health Insurance Provider

Executive Director, Healthcare Services Organisation

Consultant, Payer Strategy

Consultant (former Pharmacy Director, Pharmacy Benefit Manager)

3 Key Quotes

“Physicians saw that Zarxio was highly similar and not inferior to Neupogen, so they’re happy to use it. Cost then becomes an issue. Does it make sense for a health plan to adopt a product on formulary if the WAC [wholesale acquisition cost] is only slightly below that of the branded originator? In the end, nobody wants to lose money on biosimilars; the price has to be considerably lower versus where we are with a branded originator, otherwise nothing's going to change. There’s lots of work to be done here. If the net/net price difference isn't worth it, then why go from the brand originator to a biosimilar?” Chief Medical Officer, National Health Plan

“The FDA will need more data to approve a biosimilar as interchangeable. Companies will need to generate switching data, going from the originator to the biosimilar, and back again.”Regional Clinical Manager, National Health Plan

“Huge! Enbrel and Humira are, across many plans, the number one drug by spend. If you combine them, it would be number one in the US, full stop. Humira and Enbrel biosimilars offer a huge opportunity for savings. It'll be interesting to see whether that materialises. It'll take a little bit of time, but it could be huge.”Consultant, Payer Strategy

Who Would Benefit from This Report?

Commercial teams negotiating biosimilar prices and discounts with payers

Marketing teams communicating the benefits and safety of biosimilars

Medical affairs teams, including medical science liaisons, who are building the evidence case for biosimilars with physicians and payers, and engaging with physicians about biosimilar safety and efficacy

Market research and HEOR teams analysing long-term real world data on biosimilar use and outcomes

Payer strategy teams tasked with the job of understanding what payers are looking for from biosimilars and originator brands, and how this thinking can be changed

Content Highlights

Overview of progress in the US market

Key insights

Biosimilars remain a critical element in the war against high drug prices in the US

Biosimilar awareness levels in the US remain below where they need to be, but educational efforts are improving

The biosimilar pipeline continues to advance, with positive clinical data being published for several key pipeline programmes

Non-monoclonal antibody (mAb) programmes

Anti-TNF programmes

Targeted oncology mAb programmes

Regulatory progress continues to be made, including new guidelines, more submissions and more approvals, but concerns remain regarding a potential lack of FDA resources

Litigation remains a key offensive and defensive strategy for companies involved in the biosimilars market

Commercially things are only just getting started in the US, but ground work is paying off for some products and commercial agreements are being struck

Policy and market access debates in the US remain focused on supporting the use of biosimilars, but critics say not enough is being done to support the industry

What next for the US biosimilars market?

Biosimilar awareness and education

Key insights

Lack of hands-on, real-world experience with biosimilars is preventing all key stakeholder groups from improving their knowledge and acceptance of biosimilars in the US

No stone should be left unturned in relation to educating key stakeholders about biosimilars, with payers, physicians and patients being the key audiences

The currently regulatory environment

Key insights

Payers are supportive of the FDA guidelines, arguing the data requirements are fair and sufficient enough to get biosimilars on formulary

Payer comfort with extrapolated indications has improved rapidly over the last 12 months, but physicians might represent a different challenge

Differentiated names for biosimilars won’t impact payer decision making at all, but could help improve traceability

Payers predicted correctly what the FDA would require in its interchangeable biosimilar guideline, but also propose other avenues to gaining the much-coveted designation

While the commercial impact of interchangeable biosimilars could be considerable, some concerns remain, particularly from a patient safety and regulatory perspective

For the most part, payers don’t believe interchangeable biosimilars are better than non-interchangeable biosimilars, but some mention a willingness to pay more for them

Key considerations in the commercialisation of biosimilars

Key insights

Payers are now leveraging multiple strategies to drive better adoption of biosimilars in the US

Formulary exclusions have grown in prominence as a tactic used by payers to drive better adoption of biosimilars, but they won’t be used for all biosimilars

Payers express concern about how patients will be able to afford a biosimilar if something isn’t done about filling the ‘donut hole’ for self-injected products reimbursed via Medicare Part D

The ‘rebate trap’ remains an issue for some payers, while others argue it would become a moot point if biosimilar companies discounted their products aggressively

Value added services are a waste of money and don’t influence decision making, but biosimilar companies will need to offer something

Payers do have a lot of influence over the future of the US biosimilars market, but biosimilar companies must always consider physicians in their go-to-market strategy

Biosimilar commercialisation case studies

Key insights

Introduction

Case study 1: Zarxio

Sandoz’s early go-to-market strategy for Zarxio has not been well received by payers

Amgen’s response to Zarxio has ranged from implementing various commercial and 3 developmental lifecycle management tactics to simply manipulating the rebate for Neupogen

Payers scoff at the suggestion that a 15 percent WAC discount is enough to drive high rates or biosimilar adoption, and expect higher discounts in the future

Payers opine that unless Sandoz is more aggressive with its pricing for Zarxio, market share gains could stall in the high teens

Case study 2: Inflectra

Payers perceive a balanced and considered go-to-market strategy for Inflectra, with portfolio positioning, education and rational pricing all forming key elements

Inflectra has launched into a class with high sales, high utilisation and high price rises, and payers have become tired of attempted profiteering

While Pfizer’s end-game for Inflectra is unknown, payers believe this first anti-TNF biosimilar will bring much needed change to the US market

Janssen Biotech’s US defense strategy for Remicade seems fairly low key at this point, but Inflectra is on Janssen’s radar and signs are that Janssen is keen to compete

Switching data for Inflectra will have a positive influence on the uptake of Inflectra

Inflectra’s future market share will be shaped by aggressive discounting and a balanced reliance on newly diagnosed and established patients

Do payers believe indication-specific pricing in the anti-inflammatory space will become a common strategy?

Case study 3: Basaglar

While the opportunities for cost-effective options in the basal insulin category are significant, competition is fierce and payers are allowing more flexibility

Early suggestions are that Sanofi’s response to Basaglar has been muted, but payers are seeing signs of commercially and clinically focused arguments

Future challenges and opportunities

Key insights

Payers provide mixed views on the evolution of biologic prices in the US, but argue that prices need to come down to drive sustainability

Payers believe that portfolios will become critical to the future success of biosimilars and could improve the value propositions of other high-cost therapies

All eyes are on the next wave of anti-TNF biosimilars, including biosimilars of Enbrel and Humira

Significant challenges remain for therapeutic oncology mAb biosimilars, but payers remain optimistic that oncologists can be convinced of their benefits

Biosimilar can’t offer a ‘magic bullet’ solution to the current issues being debated in the US healthcare system, but can provide much-needed relief if they’re able to succeed

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.


Table of Contents
for Biosimilars: US Payer Perspectives [Report Updated: 01-04-2017]

  • 1.Executive summary

    2.Research objectives and methodology

    2.1Objectives

    2.2Methodology

    3.Overview of progress in the US market

    3.1Key insights

    3.2Biosimilars remain a critical element in the war against high drug prices in the US

    3.3Biosimilar awareness levels in the US remain below where they need to be, but educational efforts are improving

    3.4The biosimilar pipeline continues to advance, with positive clinical data being published for several key pipeline programmes

    3.4.1Non-monoclonal antibody (mAb) programmes

    3.4.2Anti-TNF programmes

    3.4.3Targeted oncology mAb programmes

    3.5Regulatory progress continues to be made, including new guidelines, more submissions and more approvals, but concerns remain regarding a potential lack of FDA resources

    3.6Litigation remains a key offensive and defensive strategy for companies involved in the biosimilars market

    3.7Commercially things are only just getting started in the US, but ground work is paying off for some products and commercial agreements are being struck

    3.8Policy and market access debates in the US remain focused on supporting the use of biosimilars, but critics say not enough is being done to support the industry

    3.9What next for the US biosimilars market?

    4.Biosimilar awareness and education

    4.1Key insights

    4.2Lack of hands-on, real-world experience with biosimilars is preventing all key stakeholder groups from improving their knowledge and acceptance of biosimilars in the US

    4.3No stone should be left unturned in relation to educating key stakeholders about biosimilars, with payers, physicians and patients being the key audiences

    5.The currently regulatory environment

    5.1Key insights

    5.2Payers are supportive of the FDA guidelines, arguing the data requirements are fair and sufficient enough to get biosimilars on formulary

    5.3Payer comfort with extrapolated indications has improved rapidly over the last 12 months, but physicians might represent a different challenge

    5.4Differentiated names for biosimilars won’t impact payer decision making at all, but could help improve traceability

    5.5Payers predicted correctly what the FDA would require in its interchangeable biosimilar guideline, but also propose other avenues to gaining the much-coveted designation 51

    5.6While the commercial impact of interchangeable biosimilars could be considerable, some concerns remain, particularly from a patient safety and regulatory perspective

    5.7For the most part, payers don’t believe interchangeable biosimilars are better than non-interchangeable biosimilars, but some mention a willingness to pay more for them

    6.Key considerations in the commercialisation of biosimilars

    6.1Key insights

    6.2Payers are now leveraging multiple strategies to drive better adoption of biosimilars in the US

    6.3Formulary exclusions have grown in prominence as a tactic used by payers to drive better adoption of biosimilars, but they won’t be used for all biosimilars

    6.4Payers express concern about how patients will be able to afford a biosimilar if something

    isn’t done about filling the ‘donut hole’ for self-injected products reimbursed via Medicare Part D

    6.5The ‘rebate trap’ remains an issue for some payers, while others argue it would become a moot point if biosimilar companies discounted their products aggressively

    6.6Value added services are a waste of money and don’t influence decision making, but biosimilar companies will need to offer something

    6.7Payers do have a lot of influence over the future of the US biosimilars market, but biosimilar companies must always consider physicians in their go-to-market strategy

    7.Biosimilar commercialisation case studies

    7.1Key insights

    7.2Introduction

    7.3Case study 1: Zarxio

    7.3.1Sandoz’s early go-to-market strategy for Zarxio has not been well received by payers

    7.3.2Amgen’s response to Zarxio has ranged from implementing various commercial and developmental lifecycle management tactics to simply manipulating the rebate for Neupogen

    7.3.3Payers scoff at the suggestion that a 15 percent WAC discount is enough to drive high rates or biosimilar adoption, and expect higher discounts in the future

    7.3.4Payers opine that unless Sandoz is more aggressive with its pricing for Zarxio, market share gains could stall in the high teens

    7.4Case study 2: Inflectra

    7.4.1Payers perceive a balanced and considered go-to-market strategy for Inflectra, with portfolio positioning, education and rational pricing all forming key elements 78

    7.4.2Inflectra has launched into a class with high sales, high utilisation and high price rises, and payers have become tired of attempted profiteering

    7.4.3While Pfizer’s end-game for Inflectra is unknown, payers believe this first anti-TNF biosimilar will bring much needed change to the US market

    7.4.4Janssen Biotech’s US defense strategy for Remicade seems fairly low key at this point, but Inflectra is on Janssen’s radar and signs are that Janssen is keen to compete

    7.4.5Switching data for Inflectra will have a positive influence on the uptake of Inflectra

    7.4.6Inflectra’s future market share will be shaped by aggressive discounting and a balanced reliance on newly diagnosed and established patients

    7.4.7Do payers believe indication-specific pricing in the anti-inflammatory space will become a common strategy?

    7.5Case study 3: Basaglar

    7.5.1While the opportunities for cost-effective options in the basal insulin category are significant, competition is fierce and payers are allowing more flexibility

    7.5.2Early suggestions are that Sanofi’s response to Basaglar has been muted, but payers are seeing signs of commercially and clinically focused arguments

    8.Future challenges and opportunities

    8.1Key insights

    8.2Payers provide mixed views on the evolution of biologic prices in the US, but argue that prices need to come down to drive sustainability

    8.3Payers believe that portfolios will become critical to the future success of biosimilars and could improve the value propositions of other high-cost therapies

    8.4All eyes are on the next wave of anti-TNF biosimilars, including biosimilars of Enbrel and Humira

    8.5Significant challenges remain for therapeutic oncology mAb biosimilars, but payers remain optimistic that oncologists can be convinced of their benefits

    8.6Biosimilar can’t offer a ‘magic bullet’ solution to the current issues being debated in the US healthcare system, but can provide much-needed relief if they’re able to succeed 100

    9.Appendix

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

65371 |

Report Format

PDF

FirstWord Pharma Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Biosimilars in Oncology: Update Bulletin [Feb 2016]
Introduction new KOL insights on the latest events that have the potential to shape the oncology bio...
01 Feb 2016 by FirstWord Pharma USD $995 More Info
Biosimilars in Oncology: KOL Insight
IntroductionWill physicians ever adopt Biosimilars in Oncology?Sceptical, survival focussed oncologi...
01 Jan 2016 by FirstWord Pharma USD $7,900 More Info
Biosimilars: European Payer Perspectives (2016)
IntroductionWhat’s driving the uptake of biosimilars in Europe and what still needs to be done?The E...
01 Jan 2016 by FirstWord Pharma USD $2,195 More Info
Biosimilars: Regulatory Outlook
IntroductionBiosimilars offer a chance to improve access to, and reduce spending on, life-saving bio...
01 Nov 2015 by FirstWord Pharma USD $2,195 More Info
The Future of Biosimilars 2015
IntroductionThe Future of Biosimilars 2015 offers expert insight and opinion on the key issues facin...
01 Jun 2015 by FirstWord Pharma USD $2,195 More Info
Biosimilars: US Payer Perspectives
IntroductionBiosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and...
01 Apr 2015 by FirstWord Pharma USD $2,195 More Info
Biosimilars: European Payer Perspectives
IntroductionCost is king when it comes to European biosimilars. One issue unites European healthca...
06 Jan 2015 by FirstWord Pharma USD $2,195 More Info
The Future of Biosimilars: mapping critical uncertainties and the impact of future events
IntroductionThe Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Event...
05 May 2014 by FirstWord Pharma USD $1,950 More Info
Commercialisation of Biosimilars: strategies for market penetration
IntroductionTimes, they are a-changin’—at least for the American biological product market. With fiv...
01 Nov 2013 by FirstWord Pharma USD $695 More Info
Biosimilars in Emerging Markets
IntroductionWhat are the implications for regulators, biosimilar companies and branded manufacturers...
01 Mar 2013 by FirstWord Pharma USD $665 More Info

This report is published by FirstWord Pharma

Download Free Report Summary PDF

Biosimilars: US Payer Perspectives [Report Updated: 01-04-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data